Kumar Aditya, Mittal Sonali, Parshad Rajinder, Bhattacharjee Hemanga Kumar, Sharma Raju, Kashyap Lokesh, Bhatia Rohit
Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, 110029 India.
Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.
Indian J Thorac Cardiovasc Surg. 2025 Jan;41(1):18-26. doi: 10.1007/s12055-024-01761-2. Epub 2024 Jun 13.
Traditionally, sternotomy has been the gold standard approach for the treatment of thymomas. However, interest in minimally invasive techniques such as video-assisted and robot-assisted thymectomy is gaining momentum. Concerns have been raised over the possibility of en-bloc resection using minimal access techniques due to limited working space and increased tumour manipulation leading to tumour breach and recurrence.
An observational cohort study was conducted at a tertiary referral centre from 1 April 2012 to 31 December 2020 and followed up until 31 March 2023. Consecutive patients of thymoma were evaluated for demography, symptoms and imaging preoperatively and included for the study. Post minimally invasive thymectomy, surgical, neurological and oncological outcomes were evaluated through out-patient and telephonic follow-up.
Fifty-two patients underwent minimally invasive thymectomy. Video-assisted thoracoscopic surgery for thymectomy was used in 49 patients (94.2%) with 3 (5.8%) patients undergoing robot-assisted thoracoscopic surgery. Median tumour size was 4 cm (interquartile range (IQR) 3-5) with a median operative duration of 150 min (IQR 120-180), blood loss of 135 ml (IQR 42.5-250), post-operative stay of 3 days (IQR 2-4) and no 30-day surgery related morbidity and mortality. Annual contrast-enhanced computed tomography imaging, available in 46 (88.5%) patients, showed no recurrence at a median follow-up of 43 (IQR, 21-75) months. No symptoms suggesting recurrence was noted at a median clinical follow-up of 57 (IQR 44-95.5) months and 88.5% patients were expected to survive a period of 10 years.
Minimally invasive thymectomy is technically feasible with minimal morbidity and acceptable intermediate-term oncological outcomes in patients suffering with thymoma.
Institute ethical committee approval: Ref no. IECPG-551/14.11.2018.Clinical Trial Registry of India: Ref no. CTRI/2019/04/018784.
传统上,胸骨切开术一直是治疗胸腺瘤的金标准方法。然而,对诸如电视辅助和机器人辅助胸腺切除术等微创技术的兴趣正在增加。由于工作空间有限以及肿瘤操作增加导致肿瘤破裂和复发,人们对使用微创技术进行整块切除的可能性提出了担忧。
在一家三级转诊中心于2012年4月1日至2020年12月31日进行了一项观察性队列研究,并随访至2023年3月31日。对连续的胸腺瘤患者术前进行人口统计学、症状和影像学评估,并纳入研究。微创胸腺切除术后,通过门诊和电话随访评估手术、神经和肿瘤学结局。
52例患者接受了微创胸腺切除术。49例(94.2%)患者采用电视辅助胸腔镜手术进行胸腺切除,3例(5.8%)患者采用机器人辅助胸腔镜手术。肿瘤中位大小为4cm(四分位间距(IQR)3 - 5),中位手术时间为150分钟(IQR 120 - 180),失血135ml(IQR 42.5 - 250),术后住院3天(IQR 2 - 4),无30天手术相关的发病率和死亡率。46例(88.5%)患者可获得年度增强CT成像,中位随访43(IQR,21 - 75)个月时未显示复发。中位临床随访57(IQR 44 - 95.5)个月时未发现提示复发的症状,88.5%的患者预计能存活10年。
对于胸腺瘤患者,微创胸腺切除术在技术上是可行的,发病率极低,中期肿瘤学结局可接受。
机构伦理委员会批准:编号IECPG - 551/14.11.2018。印度临床试验注册中心:编号CTRI/2019/04/018784。